17193-31-6

Basic information

• Product Name: H-DL-Phe-NH2
• Synonyms: DL-Phenylalanine amide
• CAS NO: 17193-31-6
• Molecular Formula: C₉H₁₂N₂O
• Molecular Weight: 164.2044
• Mol File: 17193-31-6.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 356.9 °C at 760 mmHg
• Flash Point: 169.7 °C
• Appearance: /
• Density: 1.143 g/cm³
• Vapor Pressure: 2.83E-05mmHg at 25°C
• Refractive Index: 1.575
• CAS DataBase Reference: H-DL-Phe-NH2(CAS DataBase Reference)
• NIST Chemistry Reference: H-DL-Phe-NH2(17193-31-6)
• EPA Substance Registry System: H-DL-Phe-NH2(17193-31-6)

Safety Data

• Hazardous Substances Data: 17193-31-6(Hazardous Substances Data)

Usage

General Description

H-DL-Phe-NH2, also known as D,L-phenylalanine amide, is a chemical compound consisting of the amino acid phenylalanine linked to an amine group. It is a synthetic analog of the natural amino acid phenylalanine. H-DL-Phe-NH2 is often used in research and pharmaceutical development for its potential therapeutic properties, such as its ability to act on the central nervous system. Additionally, H-DL-Phe-NH2 has been studied for its role in pain management and mood stabilization. It is commonly used in the scientific community as a tool to study various biological processes and pathways related to phenylalanine metabolism and neurotransmitter regulation. Overall, H-DL-Phe-NH2 is an important chemical that has potential applications in both basic research and pharmaceutical drug development.

InChI:InChI=1/C9H12N2O/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H2,11,12)/t8-/m0/s1

Upstream product

• 583-47-1 4-benzyl-oxazolidine-2,5-dione 
• 150-30-1 Phenylalanine 
• 21685-51-8 D-phenylalanine methyl ester 
• 55379-75-4 2-amino-3-phenylpropanenitrile 
• 71666-94-9 (R)-2-amino-3-phenylpropanamide hydrochloride 
• 5241-58-7 L-Phenylalanine amide 
• 5619-07-8 methyl 2-amino-3-phenylpropanoate hydrochloride 
• 15028-44-1 DL-phenylalanine methyl ester 
• 2448-45-5 Cbz-D-Phe 
• 673-06-3 D-(R)-phenylalanine 
• 5241-56-5 (R)-benzyl (1-amino-1-oxo-3-phenylpropan-2-yl)carbamate 
• 13033-84-6 D-phenylalanine methyl ester hydrochloride 
• 108321-83-1 phenylalanine amide hydrochloride 
• 3182-93-2 (L)-phenylalanine ethyl ester hydrochloride 

Downstream Products

• 65732-65-2 2-(2-Nitro-phenylsulfanylamino)-3-phenyl-propionamide 
• 112435-81-1 Boc-Phe-Leu-NH-CHCONH2 
• 63-91-2 L-phenylalanine 
• 75543-73-6 (S)-2-amino-3-phenyl-1-propylamine 
• 118247-84-0 Z-β-homo-Asp(OBut)-D-Phe-NH2 
• 85512-22-7 Boc-Tyr-D-Ala-Phe-Gly-D-Phe-NH₂ 
• 85612-59-5 (R)-3-phenylpropane-1,2-diamine 
• 125482-41-9 (R)-2-{[1-(4-Methoxy-phenyl)-meth-(E)-ylidene]-amino}-3-phenyl-propionamide 
• 5241-58-7 L-Phenylalanine amide 
• 673-06-3 D-(R)-phenylalanine 
• 5241-58-7 D-Phenylalaninamide 
• 2448-45-5 Cbz-D-Phe 
• 872035-23-9 (3S,6S,9R,1'R)-3-[9'-fluorenylmethyloxycarbonyl]-9-[(1'-carbamoyl-2'-phenyl)ethyl]carbamoyl-2-oxo-7-thio-1-azabicyclo[4.3.0]nonane 
• 872035-08-0 (2R,5R,11bS,1'R)-2-(tert-butoxycarbonyl)amino-5-[(1'-carbamoyl-2'-phenyl)ethyl]carbamoyl-3-oxo-2,3,5,6,11,11b-hexahydro-1H-indolizino[8,7-b]indole 

Relevant articles and documents

-

-

Mapping the s1 and s1’ subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents

The cysteine protease cruzipain is considered to be a validated target for therapeutic intervention in the treatment of Chagas disease. A series of 26 new compounds were designed, synthesized, and tested against the recombinant cruzain (Cz) to map its S1/S1′ subsites. The same series was evaluated on a panel of four human cysteine proteases (CatB, CatK, CatL, CatS) and Leishmania mexicana CPB, which is a potential target for the treatment of cutaneous leishmaniasis. The synthesized compounds are dipeptidyl nitriles designed based on the most promising combinations of different moieties in P1 (ten), P2 (six), and P3 (four different building blocks). Eight compounds exhibited a Ki smaller than 20.0 nM for Cz, whereas three compounds met these criteria for LmCPB. Three inhibitors had an EC50 value of ca. 4.0 μM, thus being equipotent to benznidazole according to the antitrypanosomal effects. Our mapping approach and the respective structure-activity relationships provide insights into the specific ligand-target interactions for therapeutically relevant cysteine proteases.

Synthetic method for chiral alpha-aminoamide compounds

The invention provides a synthetic method for chiral alpha-aminoamide compounds, belongs to the technical field of organic synthetic methodology, and concretely relates to a synthetic method for chiral alpha-aminoamide compounds, wherein the method has a simple process, low costs and good economy. The method comprises the following steps: 1, performing ammonolysis: adding substituted chiral alpha-aminocarboxylate hydrochloride into concentrated ammonia water, performing stirring for 4-12h under a room temperature, wherein each 1mmol substituted chiral alpha-aminocarboxylate hydrochloride is corresponding to 2-8mL the concentrated ammonia water; 2, after a reaction is finished, performing distillation for removing ammonia water after the reaction to obtain crude products chiral alpha-aminoamide compounds; and 3, performing filtration on the obtained crude products chiral alpha-aminoamide compounds by adopting a manner of adding a solvent or performing purification on the obtained crude products chiral alpha-aminoamide compounds through a manner of column chromatography which uses ammonia water as a mobile phase to obtain the products chiral alpha-aminoamide compounds. Compared with the prior art, a large number of an ammonia gas for ammonolysis is not needed in the method, the process and post-treatment are simple, costs are low and reaction time is short.